secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2026-11-10T21:27:44+00:00
Accession:  0001193125-26-455557
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Biomea Q3 net loss narrows to $6.2M; cash of $26.8M funds runway into Q2 2027
-----------------------------------------------------------------------------

- Net loss attributable to common stockholders $6.2M vs $16.4M in Q3 2025; nine-month net loss $26.9M vs $66.4M.
- R&D expense $8.5M, down $5.9M YoY on lower manufacturing, clinical and headcount costs; G&A $4.4M vs $4.2M.
- Cash, cash equivalents and restricted cash $26.8M at Sept 30, 2026; runway projected into Q2 2027.
- COVALENT-211 Phase II enrollment complete in insulin-deficient T2D; Week 26 HbA1c topline data expected Q1 2027. COVALENT-212 topline expected Q2 2027.
- BMF-650 Phase I: 6.1% (6.2 kg) mean weight loss at Day 29 in Cohort 5; 1.5-3.2% in Cohorts 1-4 vs 0.1% placebo; all TEAEs mild or moderate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000119312526455557/0001193125-26-455557-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000119312526455557/bmea-20261110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-455557

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer